3.83
+0.05(+1.32%)
Currency In USD
| Previous Close | 3.78 |
| Open | 4.17 |
| Day High | 4.35 |
| Day Low | 3.79 |
| 52-Week High | 5.88 |
| 52-Week Low | 1.64 |
| Volume | 45.9M |
| Average Volume | 11.14M |
| Market Cap | 1.27B |
| PE | -3.22 |
| EPS | -1.19 |
| Moving Average 50 Days | 2.56 |
| Moving Average 200 Days | 2.31 |
| Change | 0.05 |
If you invested $1000 in Iovance Biotherapeutics, Inc. (IOVA) 10 years ago, it would be worth $717.23 as of February 26, 2026 at a share price of $3.83. Whereas If you bought $1000 worth of Iovance Biotherapeutics, Inc. (IOVA) shares 5 years ago, it would be worth $102.68 as of February 26, 2026 at a share price of $3.83.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas
GlobeNewswire Inc.
Feb 24, 2026 12:00 PM GMT
50% Objective Response Rate (ORR) in Advanced Sarcomas Significant Market Opportunity with More than 8,000 Patients Diagnosed Annually in the U.S. and Europe SAN CARLOS, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDA
Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Updates on Tuesday, February 24, 2026
GlobeNewswire Inc.
Feb 11, 2026 9:05 PM GMT
SAN CARLOS, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patient
Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma
GlobeNewswire Inc.
Feb 05, 2026 10:15 PM GMT
52% Amtagvi Response Rate with Two or Fewer Prior Lines of Therapy 73% Overall Disease Control RateSAN CARLOS, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on inn